Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes

Documenti analoghi

• Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO‐K study)
  di: Mee Kyoung Kim, et al.
  Pubblicazione: (2025)
• Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
  di: So Ra Kim, et al.
  Pubblicazione: (2026)
• Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
  di: Kyung Ah Han, et al.
  Pubblicazione: (2024)
• Accuracy of ChatGPT , Gemini, Claude and DeepSeek in Carbohydrate Counting
  di: Luca Zagaroli, et al.
  Pubblicazione: (2026)
• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  di: Soo Lim, et al.
  Pubblicazione: (2024)